Eupraxia Pharmaceuticals Inc. (EPRX.TO)
Eupraxia Pharmaceuticals Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Victoria, BC, CA. The stock last traded at $9.11, down 2.62% on the session, giving a market capitalisation of $327.2M. Its beta of 1.50 implies it has historically moved more than the broad market.
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, targeting both critical unmet medical needs and pain management for knee osteoarthritis. This promising candidate is also being developed for veterinary use, specifically for canine and equine osteoarthritis. Eupraxia's broader development portfolio includes EP-201, an antibiotic aimed at preventing post-surgical site infections, and EP-105, an extended-release anesthetic designed for extended post-operative pain relief. Furthermore, the company is actively developing product candidates for oncology applications. Established in 2011 and headquartered in Victoria, Canada, Eupraxia Pharmaceuticals Inc. was formerly known as Plaza Capital Partners Inc. until its renaming in May 2012.
Eupraxia Pharmaceuticals Inc. is most often compared with the following Healthcare names: